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Sensitisation to Amaranthus retroflexus pollen is very common in tropical and subtropical countries. In this study we aimed to
produce a recombinant allergenic Ole e 1-like protein from the pollen of this weed. To predict cross-reactivity of this allergen (Ama
r 1) with other members of the Ole e 1-like protein family, the nucleotide sequence homology of the Ama r 1 was investigated. The
expression of Ama r 1 in Escherichia coli was performed by using a pET-21b(+) vector. The IgE-binding potential of recombinant
Ama r 1 (rAma r 1) was evaluated by immunodetection and inhibition assays using 26 patients’ sera sensitised to A. retroflexus
pollen.The coding sequence of the Ama r 1 cDNA indicated an open reading frame of 507 bp encoding for 168 amino acid residues
which belonged to the Ole e 1-like protein family. Of the 26 serum samples, 10 (38.46%) had significant specific IgE levels for rAma
r 1. Immunodetection and inhibition assays revealed that the purified rAma r 1 might be the same as that in the crude extract. Ama
r 1, the second allergen from the A. retroflexus pollen, was identified as a member of the family of Ole e 1-like protein.
1. Introduction
Pollen from Amaranthus retroflexus (redroot pigweed), a
well-known species of the Amaranthaceae family which is
found throughout the world, is an important trigger of
respiratory allergies in different regions with temperate and
dry climates, such as Saudi Arabia, Kuwait, India, Iran, the
western United States, Australia, and the Mediterranean area
[1–4]. Allergy to A. retroflexus pollen, one of the most com-
mon sources of respiratory allergies among Iranian allergy
patients, has also been well defined [1, 5]. This annual weed
is abundant in open fields and in farmlands or grasslands.
The flowering season of this plant is from around August to
October [6].
Immunochemical characterisation of the pollen extract
of A. retroflexus revealed several components ranging from
10 kDa to 85 kDa [6]. Furthermore, based on the studies of
sera of patients with respiratory allergies, the proteins of
around 10, 15, 18, 39, 45, and 85 kDa have been reported as
IgE-binding proteins from A. retroflexus pollen using allergic
patients’ sera [6, 7]. The first allergen from A. retroflexus
pollen (Ama r 2) was identified as a member of the profilin
family [8]. To the best of our knowledge, despite a high
rate of sensitisation to pollens from Amaranthus species in
different areas of theworld [1, 4, 5, 9, 10], few studies about the
molecular characterisation of A. retroflexus pollen allergens
have been conducted to date.
In this study, we introduced Ama r 1, as the second aller-
gen fromA. retroflexus pollen, which is amember of the Ole e
1-like protein family. The prototypic member of this family is
the major olive pollen allergen, Ole e 1 [11]. Several allergens
from the Ole e 1-like protein family have been identified
previously in other plants, such as Chenopodium album (Che
a 1) [12], Salsola kali (Sal k 5) [13], Fraxinus excelsior (Fra e 1)
[14], Ligustrum vulgare (Lig v 1) [15], and Syringa vulgaris (Syr
v 1) [16]. In the present study, we aimed to produce Ama r 1
in Escherichia coli and then determined the homology of its
protein sequence that was determined by comparing it with
the most common allergenic Ole e 1-like proteins.
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2. Materials and Methods
2.1. Protein Extraction from A. retroflexus Pollen. Flowers of
A. retroflexus were accumulated from August to October in
Ahvaz city, in the southwest of Iran. Gathering of pollen
materials and handling were performed by trained pollen
collectors. Floral parts other than pollenwere separated using
the sieves with different sizes (100, 200, and 300 meshes)
successively [17].
The final fine powder was subjected to a purity check
for pollen content using a microscope. Pollen materials with
more than 96% pollen and less than 4% of the other parts of
the same plant were gathered for protein extraction. Pollens
were defatted using repeated changes of diethyl ether. For
protein extraction, two grams of pollen was mixed with
12mL phosphate-buffered saline (PBS) 0.01M (pH 7.4) by
continuous stirring for 16 h at 4∘C. The supernatant was
separated by centrifugation at 13,000×g for 20min and
filtered and the supernatant collected [18].
The protein content of the extract was evaluated using
Bradford’s method [19]. Finally, the extract was freeze-dried
and stored at −20∘C for later use in the present study.
2.2. Patients’ Sera and Skin Prick Test (SPT). In this study, we
used sera from 26 patients from Ahvaz city, southwest Iran.
The patients were 12 men and 14 women (mean age, 29.88 ±
6.88 years; age range, 20–41 years) with respiratory allergies
and seasonal rhinitis who had positive skin prick test (SPT)
results forA. retroflexus pollen extract. Eight subjects without
allergies who presented with negative SPTs and no specific
IgE to the A. retroflexus pollen extract were assigned as
negative controls. All patients and control subjects gave us
their written informed consent to participate. Serum samples
of the subjects were prepared and then immediately stored at
−20∘C until used.
2.3. Total IgE and Specific Indirect Enzyme-Linked Immunosor-
bent Assays (ELISA). Total serum IgE levels were evaluated
in serum samples in duplicate using a commercially avail-
able ELISA kit according to the manufacturer’s instructions
(Euroimmun, Lu¨beck, Germany). To evaluate the levels of
specific IgE to A. retroflexus pollen proteins in patients with
respiratory allergies, an indirect ELISA was devised. In brief,
wells of an ELISA microplate (Nunc A/S, Roskilde, Den-
mark) were coated with 100 𝜇L/well of A. retroflexus pollen
extract [10 𝜇g/well in coating buffer (15mMNa
2
CO
3
, 35mM
NaHCO
3
, pH 9.6)] at 4∘C for overnight. After blocking with
a solution composed of 150 𝜇L of phosphate buffered saline
(PBS) and 2% bovine serum albumin (BSA) solution for
1 hour at 37∘C, the plates were incubated with 100 𝜇L of
patients’ sera for 3 hours at room temperature. Each well
was then incubated for 2 hours at room temperature with a
1 : 500 dilution of biotinylated goat anti-human IgE antibody
(Nordic-MUbio, Susteren, Netherlands) in 1% PBS.The wells
were then washed five times with PBS containing 0.05%
Tween-20 (T-PBS) to eliminate unbound anti-IgE. There-
after, 100 𝜇L of horseradish peroxidase- (HRP-) conjugated
streptavidin (Bio-Rad Laboratories, Hercules, CA, USA) was
placed in each well, and each well was then incubated for
1 hour at room temperature. After five washes with T-PBS,
each well received 100 𝜇L of tetramethylbenzidine substrate
solution (Sigma-Aldrich, St. Louis,MO,USA) that was placed
in eachwell, and the plate was incubated at room temperature
for 20min before the reaction was stopped by addition of
100 𝜇L of 2M HCl. Subsequently, the absorbance in each
well was measured at 450 nm using an ELISA plate reader.
All results were expressed as optical density (OD) units. An
OD value four times higher than the average values of three
determinations of a pooled sera from negative controls (i.e.,
>0.15 OD units) was considered to be positive.
2.4. Subcloning of Ama r 1 Allergen cDNA and DNA Sequen-
cing. Total RNA was extracted from 100mg of A. retroflexus
pollen by using the Chomczynski and Sacchi method
[20]. The first strand of cDNA was synthesised using the
RevertAidTM First Strand cDNA Synthesis Kit (Thermo Sci-
entific, Waltham, MA, USA) according to the manufac-
turer’s instructions. The primers used for cDNA amplifi-
cation were designed according to the known nucleotide
sequence for reported allergens from the Ole e 1-like protein
family that have a high degree of amino acid sequence
identity [12–14, 21–23]. These primers include the sense 5󸀠-
ATGGGGAAGTGTCAAGCTGT-3󸀠 and the antisense 5󸀠-
TTAATTAGCTTTAACATCATAAAGATCC-3󸀠. The ampli-
fied fragment was ligated into a PTZ57R/T TA cloning vector
using the InsTAcloneTM PCR Cloning Kit (Thermo Scien-
tific, Waltham, MA, USA), according to the manufacturer’s
instructions. E. coli TOP10 cells (Invitrogen, Carlsbad, CA,
USA) were transformed with the ligation products using the
manufacturer’s protocol. A recombinant plasmidwas selected
bywhite/blue screening and then purified from the gel using a
plasmid extraction kit (GeNet Bio, Chungnam, Korea). DNA
sequence analysis was performed using the dideoxy method
at the Bioneer Inc. (Daejeon, Korea).
The obtained sequence was submitted to the GenBank
database of the National Center for Biotechnology Informa-
tion (http://www.ncbi.nlm.nih.gov/) under accession num-
ber KR870437.
2.5. Construction of Prokaryote Expression Vector and Pro-
duction of Recombinant Ama r 1 (rAma r 1). To create a
pET-21b(+) expression plasmid (Novagen, Gibbstown, NJ,
USA), restriction sites of Not I and Xho I restriction enzyme
sites were introduced at the 5󸀠- and 3󸀠-ends of the Ama r
1 cDNA by the polymerase chain reaction (PCR) method
using two specific primers as follows: the sense primer 5󸀠-
TCCgcggccgcATGGGGAAGTGTCAAGCTGT-3󸀠 (Not I
restriction site is in lowercase) and the antisense primer 5󸀠-
CCctcgagTTAATTAGCTTTAACATCATAAAGATCC-3󸀠
(Xho I restriction site is in lowercase). After PCR amplifi-
cation, the resulting product was digested with Not I and
Xho I restriction enzymes according to the manufacturer’s
protocol (Thermo Scientific, Waltham, MA, USA). The puri-
fied digested PCR product was ligated into the digested pET-
21b(+) plasmid with the same enzymes. Correct constructs
were transformed into competent E. coli BL21 (DE3) cells
(Novagen, Gibbstown, NJ, USA).
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A clone of recombinant plasmid pET-21b(+)/Ama r 1 was
inoculated into 2mL of lysogeny broth (LB) medium con-
taining 100 𝜇g/mL of ampicillin and incubated at 37∘C.
Expression of the recombinant protein was induced by
adding isopropyl 𝛽-d-thiogalactopyranoside (IPTG) to a
final concentration of 0.5mM [18]. Afterwards, the cells were
harvested by centrifugation (3,500×g for 15min at 4∘C),
resuspended in lysis buffer (50mM Tris-HCl pH 6.8, 15mM
imidazole, 100mM NaCl, 10% glycerol, and 0.5% Triton X-
100), and then disrupted by sonication. Purification of rAma
r 1 was performedwithNi-nitrilotriacetic acid (NTA) agarose
(Invitrogen, Carlsbad, CA, USA) from the soluble phase of
lysate according to the manufacturer’s instructions.
2.6. Determination of Specific IgE Levels to rAma r 1. In order
to assess the serum IgE levels to the purified rAma r 1, an
indirect ELISAwas developed as described above, except that
the wells of the ELISA microplate were coated with 100 𝜇L/
well of the purified rAma r 1 at a concentration of 2 𝜇g/mL
in coating buffer (15mM Na
2
CO
3
and 35mM NaHCO
3
, pH
9.6) overnight at 4∘C.The results were expressed in OD units.
Based on the mean value of two normal sera, OD
450
greater
than three times the median values of negatives controls was
considered to be positive.
2.7. ELISA Inhibition Assays for rAma r 1. ELISA inhibition
was performed as described above, except for a pooled serum
(1 : 2 vol/vol) from patients allergic to A. retroflexus (patients
1, 2, 4, 6, and 8), which was preincubated for overnight at 4∘C
with either 1000, 100, 10, 1, 0.1, or 0.01 𝜇g of rAma r 1 as an
inhibitor or with BSA as a negative control. The inhibition
percentage was calculated using the following relationship:
% Inhibition = (OD of sample without inhibitor −OD of sample with inhibitor
OD of sample without inhibitor
) × 100. (1)
2.8. IgE-Immunoblotting and IgE-Immunoblotting Inhibition
for rAma r 1. Proteins from A. retroflexus pollen extract and
E. coli lysate and purified rAma r 1 were analysed by sodium
dodecylsulphate polyacrylamide gel electrophoresis (SDS-
PAGE) using 12.5% acrylamide separation gels and under
reducing conditions according to the method of Laemmli
[24]. The molecular masses of protein bands were estimated
with Image Lab analysis software (Bio-Rad Laboratories,
Hercules, CA, USA) and compared with protein markers of
known molecular weights (Amersham low molecular weight
calibration kit for SDS electrophoresis; GE Healthcare, Little
Chalfont, UK). Separated protein bands from the elec-
trophoresis of A. retroflexus pollen were electrotransferred to
polyvinylidene difluoride (PVDF) membranes (GE Health-
care, Little Chalfont, UK), as described elsewhere [18]. In
brief, after blocking andwashing,membranes were incubated
with a serum pool or individual sera from patients with A.
retroflexus allergy or with control sera (1 : 5 dilutions) for
3 hours. Biotinylated goat anti-human IgE (Nordic-MUbio,
Susteren, Netherlands) (1 : 1000 vol/vol in PBS) was added to
the blotted membrane strips and incubated for 2 hours at
room temperature. The unbound antibodies were removed
from blots by washing with T-PBS and incubated at
1 : 10,000 vol/vol in T-PBS-HRP-linked streptavidin (Sigma-
Aldrich, St. Louis, Mo, USA) for 1 hour at room temperature.
After several washes with T-PBS, strips were incubated using
the SuperSignal West Pico Chemiluminescent Substrate Kit
(Thermo Scientific, Waltham, MA, USA) for 5 minutes,
and proteins were then visualised by chemiluminescence
using the ChemiDoc XRS+ System (Bio-Rad Laboratories,
Hercules, CA, USA).
To study cross-inhibition among natural and recombi-
nant Ama r 1, a mixture of 100 𝜇L of pooled serum (1 : 5 vol/
vol) was incubated with natural A. retroflexus pollen extract
(65 𝜇g/mL, as an inhibitor), rAma r 1 (10 𝜇g/mL, as an inhib-
itor), or BSA (as a negative control) overnight at 4∘C with
shaking. Preincubated sera were used to assess the reactivity
of a PVDF membrane blotted with natural A. retroflexus
pollen extract and rAma r 1.
3. Results
3.1. Measurement of Total and Specific IgE. The mean total
IgE serum in the subjects was determined as 256.33 IU/mL.
In patients reactive to Ama r 1, the mean of total IgE was
183.80 IU/mL (Table 1). Sera from 26 allergic patients were
assessed for specific IgE binding to proteins from A.
retroflexus pollen extract. All of these patients had sig-
nificantly elevated specific IgE levels to the extract of A.
retroflexus pollen (mean OD
450
= 1.47 ± 0.50; range, 0.79–
2.21). The mean OD
450
for specific IgE in patients reactive to
rAma r 1 was 0.95 ± 0.16 (range, 0.78–1.23) (Table 1).
3.2. Nucleotide and Protein Sequence Analysis of Ama r 1. The
sequence analysis of Ama r 1 indicated an open reading frame
of 507 bp coding for 168 amino acid residues with a predicted
molecular mass of 18.379 kDa and a calculated isoelectric
point (pI) of 4.70. We compared the deduced amino acid
sequence of Ama r 1 with other allergenic plant-derived Ole
e 1-like proteins in the protein database (Figure 1), and we
detected a high level of sequence identity (93%) that was
detected between Ama r 1 and Che a1 (Table 2).
3.3. SDS-PAGE and IgE-Binding Components of A. retroflexus
Pollen Extract. The reducing SDS-PAGE separation of the
pollen extract showed several resolved protein bands in the
A. retroflexus pollen extract with molecular weights ran-
ging from approximately 10 to 85 kDa (Figure 2). IgE-binding
reactivity of the separated protein bands from the electropho-
resis of the A. retroflexus pollen extract was assessed by con-
ducting immunoblotting experiments. The results revealed
that several IgE-reactive bands range from about 15 to 85 kDa.
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Table 1: Clinical attribute, skin prick test responses, and specific IgE values of patients reactive to recombinant Ama r 1.
Patients number Age (years)/gender1 Symptoms2 Total IgE (IU/mL) A. retroflexus pollen extract rAma r 1-specific IgE
Skin prick test3 Specific IgE4
1 38/M A, R 152 8 1.80 0.95
2 32/F A, R, L 185 12 2.10 1.23
3 21/F A, R 162 8 0.98 0.80
4 38/F A, R, L 224 12 1.89 1.10
5 23/M A, R, L 132 10 1.10 0.84
6 29/F A, R, L 166 12 1.95 0.98
7 41/M A, R 175 9 0.92 0.81
8 32/F A, R, L 305 15 2.21 1.15
9 22/M A, R 159 11 1.12 0.87
10 35/F A, L 178 10 0.97 0.78
1M: male; F: female.
2A: allergic rhinitis; L: lung symptoms (breathlessness, tight chest, cough, and wheeze); R: rhinoconjunctivitis.
3Themean wheal areas are displayed in mm2. Histamine diphosphate (10mg/mL)—positive control; Glycerin—negative control.
4Determined in specific ELISA as OD (optical density) at 450 nm.
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Figure 1: Comparison of the A. retroflexusOle e 1-like protein (Ama r 1) amino acid sequence with allergenic Ole e 1-like protein from other
plants. Chenopodium album (Che a 1, G8LGR0.1), Crocus sativus (Cro s 1, XP004143635.1), Salsola kali (Sal k 5, ADK22842.1), Olea europaea
(Ole e 1, P19963.2), Fraxinus excelsior (Fra e 1, AAQ83588.1), Syringa vulgaris (Syr v 1, S43243), and Ligustrum vulgare (Lig v 1, O82015.2). The
amino acid sequence identity and the similarity ofAma r 1 (KR870437) to othermembers of theOle e 1-like family are shown inTable 2.The top
line indicates the location of secondary structures that are created by PSIPRED protein sequence analysis (http://bioinf.cs.ucl.ac.uk/psipred/).
The cylinder, arrows, and black line correspond to alpha-helices, beta-strands, and coil structure, respectively.
Journal of Allergy 5
Table 2: Percentage of similarity and identity between Ama r 1 and
selected allergenic Ole e 1-like proteins.
Allergens∗ GenBank accession number Ama r 1
% Similarity % Identity
Che a 1 G8LGR0.1 95 93
Cro s 1 AAX93750.1 95 91
Sal k 5 ADK22842.1 88 70
Ole e 1 ABP58635.1 61 43
Fra e 1 AAQ83588.1 62 42
Lig v 1 O82015.2 61 40
Syr v 1 S43243 60 42
∗Che a 1 (C. album); Cro s 1 (C. sativus); Sal k 5 (S. kali); Ole e 1 (O. europaea);
Fra e 1 (F. excelsior); Syr v 1 (S. vulgaris); and Lig v 1 (L. vulgare).
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Figure 2: SDS-PAGE and immunoreactivity of A. retroflexus pollen
extract. Lane MW: molecular weight marker (GE Healthcare, Little
Chalfont, UK); lane 1: Coomassie Brilliant Blue-stained SDS-PAGE
of the crude extract of A. retroflexus pollen (12.5% acrylamide gel);
and lane 2: immunoblotting ofA. retroflexus pollen extract.The strip
was first blottedwithA. retroflexuspollen extract and then incubated
with pooled sera of patients allergic to A. retroflexus (patients 1, 2, 4,
6, and 8) and detected for IgE reactive protein bands. Natural Ama
r 1 is indicated by white arrow.
3.4. Expression and Purification of Ama r 1 Protein. ApET-21b
(+)/Ama r 1 clone was constructed and confirmed by diges-
tion with Not I and Xho I restriction enzymes. This recom-
binant plasmid was expressed in E. coli strain BL21 (DE3)
pLysS as a fusion protein with a His
6
-tag in the C-terminus.
rAma r 1 was present in a soluble form in the supernatant,
where it was further purified by Ni2+ affinity chromatog-
raphy to yield purified protein. The purified rAma r 1 was
quantified by using Bradford’s protein assay, which showed
that approximately 17mg of recombinant protein had been
purified from 1 L of the bacterial expression medium. SDS-
PAGE revealed that the apparent molecular weight of the
fusion proteinwas about 19 kDa (Figure 3).The allergenicOle
e 1-like protein from A. retroflexus pollen, as a new allergen,
was designated Ama r 1 by the WHO/International Union
of Immunological Societies (IUIS) Allergen Nomenclature
Subcommittee (http://www.allergen.org/).
3.5. Specific IgE ELISA of rAma r 1. The levels of specific IgE
to the purified rAma r 1 were determined using 26 individual
patients’ sera. Of the 26 patients, 10 (38.46%) had significant
specific IgE levels to rAma r 1 (Table 1). Serum samples from
the patients allergic to A. retroflexus pollen were further
tested for IgE reactivity to rAma r 1 by immunoblotting
assays. The results showed that the recombinant form of
Ama r 1 was reactive with 10 individuals’ sera. These results
were consistent with those obtained by specific IgE ELISA
(Table 1).
3.6. In Vitro Inhibition Assays. ELISA inhibition experiments
were performed to evaluate the IgE-binding capacity of the
purified rAma r 1 compared with its natural counterpart in
A. retroflexus pollen extract. The ELISA inhibition results
revealed a dose-dependent inhibition of the IgE directed
towards rAma r 1 in patients’ sera positive to A. retroflexus.
Preincubation of pooled serawith 1mg/mLof rAma r 1 andA.
retroflexus pollen extract showed significant inhibition (86%
and 80%, resp.) of IgE binding to rAma r 1 inmicroplate wells
(Figure 4).
Immunoblot inhibition assays indicated that preincuba-
tion of serum samples with rAma r 1 almost completely
inhibited the IgE binding to a protein band with an apparent
molecular weight of 19 kDa (Figure 5, line 3). Altogether, in
vitro inhibition assays showed a similar IgE reactivity for
rAma r 1 and its natural counterpart in A. retroflexus pollen
extract. In addition, the results indicated that preincubation
of serum samples with native crude extract of A. retroflexus
pollen completely inhibited the IgE binding to natural Ama
r 1 counterparts in A. retroflexus pollen extract and other
reactive proteins (Figure 5, line 2). However, preincubation
of the pooled sera with BSA did not affect the IgE reactivity
to rAma r 1 (Figure 5, line 1).
4. Discussion
A. retroflexus is a weed broadly distributed across wastelands
and farms in various climates, and it produces such a large
quantity of pollen that it has become one of the most aller-
genic weeds in different countries throughout the world [1–
5, 10]. In this study, the cloning and production of the second
allergen of the A. retroflexus pollen is reported. This allergen
was shown to be a member of Ole e 1-like protein family,
and, in accordance with the IUIS Allergen Nomenclature
Subcommittee, was designated as Ama r 1. Several allergens
from this family, such as Sal k 5, Che a 1, Cro s 1, Pla l 1, Syr v 1,
Lig v 1, and Fra e 1, have been recognised in previous studies
[12–14, 21–23].
The open reading frame of Ama r 1 contained a sequence
encoding an 18.37 kDa protein related to the molecular spec-
ifications of a known plant Ole e 1-like protein family [13, 14,
21]. Until now, several members of Ole e 1-like protein aller-
gens from different plant sources have been reported with
6 Journal of Allergy
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Figure 3: SDS-PAGE and immunoreactivity of recombinant Ama r 1 (rAma r 1). (a) Lane MW: molecular weight marker (GE Healthcare,
Little Chalfont, UK); lane 1: Coomassie Brilliant Blue-stained SDS-PAGEof soluble fraction of cell culture (IPTG-induced pET-21b(+) without
insert); lane 2: rAma r 1 (IPTG-induced pET-21b(+)/Aca f 1) in soluble fraction; and lane 3: purified rAma r 1 (as an approximately 19 kDa
recombinant protein) with Ni-NTA affinity chromatography on 12.5% acrylamide gel. (b) IgE immunoblot of purified rAma r 1 using sera of
patients with respiratory allergies. Lanes 1–10: probed with sera from patients with positive for rAma r 1; lane NTC: negative control.
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Figure 4: ELISA inhibition with A. retroflexus pollen extract and
rAca f 1. Inhibition of IgE binding to rAca f 1 by ELISA using A.
retroflexus pollen extract and rAma r 1. Control experiments were
performed with BSA.
various molecular weights, such as 17.08–17.62 kDa in two
members of the Amaranthaceae family (Che a 1, Sal k 5),
20 kDa in C. sativus pollen (Cro s 1), and 17–20 kDa (gly-
cosylated and nonglycosylated) in Plantago lanceolata (Pla l
1) [13, 22, 25]. These relative disparities in molecular weight
may be due to differences in some amino acid residues, levels
of glycosylation, or molecular weight measurement methods
97.0
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30.0
20.1
14.4
(kDa) MW 2 31
Figure 5: Immunoblotting inhibition assays. Lane MW: molecular
weight marker (GE Healthcare, UK); lane 1: A. retroflexus protein
strip incubated with pooled sera without inhibitor (negative con-
trol); lane 2: A. retroflexus protein strip incubated with pooled sera
containing 65 𝜇g of A. retroflexus pollen extract as an inhibitor
(positive control); and lane 3: A. retroflexus protein strip incubated
with pooled sera containing 10𝜇g purified rAma r 1, as an inhibitor.
MWs methods. Ama r 1, like Che a 1, Cro s 1, and Sal k 5, has
a conserved sequence for potential N-linked glycosylation in
the same position of the polypeptide chain (Asn-Ile/Leu-Thr-
Ala), which is actually engaged by a glycan in these proteins.
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Immunoblotting assays of A. retroflexus pollen extract
using pooled sera from the patients also revealed an IgE-
binding protein band with an estimated molecular weight of
19 kDa (Figure 1). The IgE-binding capability of the purified
rAma r 1 to sera from patients with A. retroflexus allergies
was evaluated by specific ELISA and immunoblotting assays
to confirm that rAma r 1 was correctly folded and bound to
IgE as the natural counterpart in A. retroflexus extract. The
purified rAma r 1 was recognised in 10 patients allergic to the
A. retroflexus pollen extract (10/26, 38.4%).
The results of immunoblotting assays for natural Ama
r 1 with a molecular weight of 19 kDa were consistent with
those obtained for rAma r 1. A nearly complete inhibition
of IgE-binding to natural Ama r 1 was also obtained after
preincubation of pooled sera with purified rAma r 1. It seems
that rAma r 1 is composed of IgE epitopes similar to those of
its natural counterpart.
Cross-reactivity between A. retroflexus pollen compo-
nents and other allergenic members of the Amaranthaceae
family (S. kali, C. album, and Kochia scoparia) and some
unrelated allergenic plants such as Acacia farnesiana and
Prosopis juliflora has been described previously [6, 7, 17].
The present study was conducted to detect the amino acid
sequence homology of Ole e 1-like proteins from allergenic
regional plants. The results of amino acid sequence identity
analysis indicated that Ama r 1 protein has a great degree
of identity with the selected allergenic Ole e 1-like protein
family from the most common allergenic regional plants,
particularly C. album (Che a 1), C. sativus (Cro s 1), and S.
kali (Sal k 5) (93%, 91%, and 70%, resp.). Identification of the
Ama r 1 sequence will warrant further studies on the basis
of in vitro assays to investigate the molecular basis of cross-
reactivity among these important pollen allergens.
5. Conclusion
In conclusion, in this study, we investigated a new allergen
from A. retroflexus pollen, Ama r 1, with a detectably specific
IgE in 38.4%of patients allergic toA. retroflexus pollen. Ama r
1 was identified as a member of the Ole e 1-like protein family.
In addition, the results demonstrate that rAma r 1 expressed
in E. coli has immunoreactivity similar to that of the natural
form of the allergen. Analysis of the amino acid sequences
of Ama r 1 and several allergenic members of the Ole e
1-like protein family from other plants also indicated that
cross-reactivity between plants belongs to unrelated families,
whichmay be predicted by the degree of amino acid sequence
identity of potential conformational epitopes.
Concerning the more prevalent of sensitisation to A.
retroflexus pollen and the abundance of it in different coun-
tries throughout the world, identification and production of
the recombinant forms of common allergens of this pollen
may lead to the exploration of new guidelines for diagnostic,
therapeutic, and preventive purposes.
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